Medifacts Announces $3.1 Million Study Award with a Top 5 Pharmaceutical Company

Mon, 05/04/2009 - 7:39am
Medifacts International, Inc., a global provider of noninvasive cardiac diagnostic services, has announced the award of a $3.1 million contract with a top 5 global pharmaceutical company to provide comprehensive cardiac safety and efficacy services for a large late stage clinical trial. Demonstrating a unique ability to combine multiple technology platforms in one offering, Medifacts will provide equipment and services for the electronic collection of four different data types including Pulse Wave Analysis, Blood Pressure and Telemedicine support of subjects in the home setting across 16 countries worldwide. Michael Woehler, Medifacts International's President and Chief Executive Officer said: “We are excited the industry continues to recognize the superior quality of Medifacts' global services and entrust us with their key programs. Medifacts and our WebHeart® platform continue to set the global standard in cardiac safety and efficacy data collection, management and submission. Medifacts International's commitment to our sponsors' rigorous expectations continues to pay dividends as we advance our position as one of the top 3 global cardiac safety businesses.”

Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.